Byondis Appoints Christoph Korpus as Chief Business Officer
Christoph Korpus, PhD, MBA, Chief Business Officer, Byondis ∙ Photo Credit: Byondis
Corporate Business News Sponsored by VS News Network
NIJMEGEN, The Netherlands, March 22, 2025 (BUSINESS WATCH GLOBAL) — Biopharmaceutical company, Byondis B.V., has appointed Christoph Korpus, PhD, MBA, as Chief Business Officer.
According to the company, Korpus will lead business development initiatives and support the clinical advancement of its pipeline of antibody-drug conjugates and monoclonal antibody-based therapeutics.
Korpus has more than 15 years of experience in the pharmaceutical industry. Prior to joining Byondis, he served as Director of Global Business Development and Licensing Oncology at Merck KGaA, Darmstadt, Germany. In that role, he developed partnering strategies and led negotiation teams for oncology-related transactions. He previously managed global commercial and development alliances within the company.
Korpus began his career as a pharmacist. He holds a degree in Pharmacy from Goethe-University in Frankfurt am Main, Germany, a PhD from Ludwig-Maximilians-Universität Munich and the University of Connecticut, and an MBA from the Kellogg School of Management at Northwestern University and WHU-Otto Beisheim School of Management.
"Christoph will play a pivotal role in advancing our pipeline of novel antibody conjugates and monoclonal antibody-based therapeutics through clinical development and lead Byondis' business development efforts. With his strong strategic leadership, deep experience in successful partnering and alliance building, along with his background in Oncology drug development, Christoph will be a valuable addition to our leadership team," said Jacques Lemmens, Founder and CEO of Byondis.
"I am energized to bring my experience to Byondis and to join such an innovative company that is on a mission to make hope real for patients. I believe Byondis, with its fully-integrated research, development and manufacturing capabilities, is uniquely positioned to bring a new generation of ADCs and antibody-based therapies to patients with cancer. I look forward to contributing to the company’s progress and growth," said Korpus.
Byondis is an independent clinical stage biopharmaceutical company focused on developing new biological entities, with an emphasis on antibody-drug conjugates and antibody-based therapeutics. The company operates from its research and manufacturing facilities in Nijmegen, the Netherlands.
For more information, visit www.byondis.com.
Source: Byondis B.V.
